Pelthos Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTHS research report →
About the company
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older.
- CEO
- Scott Plesha
- IPO
- 2025
- Employees
- 4
- HQ
- Durham, NC, US
Price Chart
- Market Cap
- $16.71M
- P/E
- -0.63
- P/S
- 0.60
- P/B
- 2.43
- EV/EBITDA
- -0.74
- Div Yield
- 0.00%
- Gross Margin
- 47.02%
- Op Margin
- -157.70%
- Net Margin
- -186.23%
- ROE
- -164.11%
- ROIC
- -31.58%
- Revenue
- $16.80M · 0.00%
- Net Income
- $-43,319,000 · -444.53%
- EPS
- $-23.04 · -70.16%
- Op Income
- $-32,430,000
- FCF YoY
- -291.70%
- 52W High
- $54.29
- 52W Low
- $16.09
- 50D MA
- $26.54
- 200D MA
- $26.47
- Beta
- 3.13
- Avg Volume
- 21.89K
Get TickerSpark's AI analysis on PTHS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Friedberg Ezra M | sell | 224 |
| Jun 15, 26 | Friedberg Ezra M | sell | 59 |
| Jun 11, 26 | Davis Todd C | buy | 503 |
| Jun 11, 26 | Davis Todd C | buy | 35,445 |
| May 22, 26 | Francis Knuettel II | other | 59,500 |
| May 22, 26 | Francis Knuettel II | sell | 13,947 |
| May 22, 26 | Francis Knuettel II | sell | 1,500 |
| May 22, 26 | Francis Knuettel II | sell | 42,500 |
| May 14, 26 | Friedberg Ezra M | other | 144 |
| Apr 10, 26 | GAY JOHN M. | other | 0 |
Our PTHS coverage
Recent articles, reports, and earnings notes.
No research on PTHS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTHS report →Similar companies
Peers in the same neighborhood.